Clearmind Medicine’s new MEAI patent and first‑cohort AUD data show breakthrough neuro‑plasticity treatments for cocaine and alcohol addiction, boosting investor and clinical interest.

Clearmind Medicine Inc. has achieved a major milestone in its efforts to combat Alcohol Use Disorder (AUD) with the successful dosing of its innovative CMND-100 treatment in a Phase I/IIa clinical trial.